Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 10/2003

01.10.2003 | Article

Risk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients

verfasst von: V. C. C. Cheng, W. C. Yam, P. C. Y. Woo, S. K. P. Lau, I. F. N. Hung, S. P. Y. Wong, W. C. Cheung, K. Y. Yuen

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

The risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20–109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672±315 cells/μl vs. 1,328±467 cells/μl; P<0.001), and to exhibit a greater surge in lymphocyte counts (627±465 cells/μl vs. 225±216 cells/μl; P<0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.
Literatur
1.
Zurück zum Zitat Cheng VC, Ho PL, Lee RA, Chan KS, Chan KK, Woo PC, Lau SK, Yuen KY (2002) Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis 21:803–809CrossRefPubMed Cheng VC, Ho PL, Lee RA, Chan KS, Chan KK, Woo PC, Lau SK, Yuen KY (2002) Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis 21:803–809CrossRefPubMed
2.
Zurück zum Zitat Al-Majed SA (1996) Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Respir Med 90:211–214PubMed Al-Majed SA (1996) Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Respir Med 90:211–214PubMed
3.
Zurück zum Zitat Campbell IA, Dyson AJ (1977) Lymph node tuberculosis: a comparison of various methods of treatment. Tubercle 58:171–179PubMed Campbell IA, Dyson AJ (1977) Lymph node tuberculosis: a comparison of various methods of treatment. Tubercle 58:171–179PubMed
4.
Zurück zum Zitat Memish ZA, Mah MW, Mahmood SA, Bannatyne RM, Khan MY (2000) Clinico-diagnostic experience with tuberculous lymphadenitis in Saudi Arabia. Clin Microbiol Infect 6:137–141PubMed Memish ZA, Mah MW, Mahmood SA, Bannatyne RM, Khan MY (2000) Clinico-diagnostic experience with tuberculous lymphadenitis in Saudi Arabia. Clin Microbiol Infect 6:137–141PubMed
5.
Zurück zum Zitat Mofredj A, Guerin JM, Leibinger F, Masmoudi R (1996) Paradoxical worsening in tuberculosis during therapy in an HIV-infected patient. Infection 24:390–391PubMed Mofredj A, Guerin JM, Leibinger F, Masmoudi R (1996) Paradoxical worsening in tuberculosis during therapy in an HIV-infected patient. Infection 24:390–391PubMed
6.
Zurück zum Zitat Chien JW, Johnson JL (1998) Paradoxical reactions in HIV and pulmonary TB. Chest 114:933–936PubMed Chien JW, Johnson JL (1998) Paradoxical reactions in HIV and pulmonary TB. Chest 114:933–936PubMed
7.
Zurück zum Zitat Narita M, Ashkin D, Hollender ES, Pitchenik AE (1998) Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 158:157–161 Narita M, Ashkin D, Hollender ES, Pitchenik AE (1998) Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 158:157–161
8.
Zurück zum Zitat Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR (2001) Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 120:193–197PubMed Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR (2001) Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 120:193–197PubMed
9.
Zurück zum Zitat John M, French MA (1998) Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998 169:473–474 John M, French MA (1998) Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998 169:473–474
10.
Zurück zum Zitat Furrer H, Malinverni R (1999) Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Am J Med 106:371–372CrossRefPubMed Furrer H, Malinverni R (1999) Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Am J Med 106:371–372CrossRefPubMed
11.
Zurück zum Zitat Ramdas K, Minamoto GY (1994) Paradoxical presentation of intracranial tuberculomas after chemotherapy in a patient with AIDS. Clin Infect Dis 19:793–794PubMed Ramdas K, Minamoto GY (1994) Paradoxical presentation of intracranial tuberculomas after chemotherapy in a patient with AIDS. Clin Infect Dis 19:793–794PubMed
12.
Zurück zum Zitat Crump JA, Tyrer MJ, Lloyd-Owen SJ, Han LY, Lipman MC, Johnson MA (1998) Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 26:1008–1009PubMed Crump JA, Tyrer MJ, Lloyd-Owen SJ, Han LY, Lipman MC, Johnson MA (1998) Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 26:1008–1009PubMed
13.
Zurück zum Zitat Eyer-Silva WA, Pinto JF, Arabe J, Morais-De-Sa CA (2002) Paradoxical reaction to the treatment of tuberculosis uncovering previously silent meningeal disease. Rev Soc Bras Med Trop 35:59–61PubMed Eyer-Silva WA, Pinto JF, Arabe J, Morais-De-Sa CA (2002) Paradoxical reaction to the treatment of tuberculosis uncovering previously silent meningeal disease. Rev Soc Bras Med Trop 35:59–61PubMed
14.
Zurück zum Zitat Orlovic D, Smego RA Jr (2001) Paradoxical tuberculous reactions in HIV-infected patients. Int J Tuberc Lung Dis 5:370–375PubMed Orlovic D, Smego RA Jr (2001) Paradoxical tuberculous reactions in HIV-infected patients. Int J Tuberc Lung Dis 5:370–375PubMed
15.
Zurück zum Zitat Navas E, Martin-Davila P, Moreno L, Pintado V, Casado JL, Fortun J, Perez-Elias MJ, Gomez-Mampaso E, Moreno S (2002) Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 162:97–99CrossRefPubMed Navas E, Martin-Davila P, Moreno L, Pintado V, Casado JL, Fortun J, Perez-Elias MJ, Gomez-Mampaso E, Moreno S (2002) Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 162:97–99CrossRefPubMed
16.
Zurück zum Zitat Ramos A, Asensio A, Perales I, Montero MC, Martin T (2003) Prolonged paradoxical reaction of tuberculosis in an HIV-infected patient after initiation of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 22:374–376PubMed Ramos A, Asensio A, Perales I, Montero MC, Martin T (2003) Prolonged paradoxical reaction of tuberculosis in an HIV-infected patient after initiation of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 22:374–376PubMed
17.
Zurück zum Zitat Cheng VC, Woo PC, Lau SK, Cheung CH, Yung RW, Yam LY, Yuen KY (2003) Peripartum tuberculosis: a form of immunorestitution disease. Eur J Clin Microbiol Infect Dis 22:313–317PubMed Cheng VC, Woo PC, Lau SK, Cheung CH, Yung RW, Yam LY, Yuen KY (2003) Peripartum tuberculosis: a form of immunorestitution disease. Eur J Clin Microbiol Infect Dis 22:313–317PubMed
18.
Zurück zum Zitat Valdez LM, Schwab P, Okhuysen PC, Rakita RM (1997) Paradoxical subcutaneous tuberculous abscess. Clin Infect Dis 24:734 Valdez LM, Schwab P, Okhuysen PC, Rakita RM (1997) Paradoxical subcutaneous tuberculous abscess. Clin Infect Dis 24:734
19.
Zurück zum Zitat Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM (2000) Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 30:882–892PubMed Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM (2000) Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 30:882–892PubMed
20.
Zurück zum Zitat Cheng VC, Yuen KY, Wong SS, Woo PC, Ho PL, Lee R, Chan RM (2001) Immunorestitution diseases in patients not infected with HIV. Eur J Clin Microbiol Infect Dis 20:402–406PubMed Cheng VC, Yuen KY, Wong SS, Woo PC, Ho PL, Lee R, Chan RM (2001) Immunorestitution diseases in patients not infected with HIV. Eur J Clin Microbiol Infect Dis 20:402–406PubMed
21.
Zurück zum Zitat Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC (2001) Global trends in resistance to antituberculosis drugs. N Engl J Med 344:1294–1303PubMed Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC (2001) Global trends in resistance to antituberculosis drugs. N Engl J Med 344:1294–1303PubMed
22.
Zurück zum Zitat Kam KM, Yip CW, Tse LW, Leung OC, Sin LP, Chan MY, Wong WS (2002) Trends in multidrug-resistant Mycobacterium tuberculosis in relation to sputum smear positivity in Hong Kong, 1989–1999. Clin Infect Dis 34:324–329CrossRefPubMed Kam KM, Yip CW, Tse LW, Leung OC, Sin LP, Chan MY, Wong WS (2002) Trends in multidrug-resistant Mycobacterium tuberculosis in relation to sputum smear positivity in Hong Kong, 1989–1999. Clin Infect Dis 34:324–329CrossRefPubMed
23.
Zurück zum Zitat Ohno H, Koga H, Kuroita T, Tomono K, Ogawa K, Yanagihara K, Yamamoto Y, Miyamoto J, Tashiro T, Kohno S (1997) Rapid prediction of rifampin susceptibility of Mycobacterium tuberculosis. Am J Respir Crit Care Med 155:2057–2063PubMed Ohno H, Koga H, Kuroita T, Tomono K, Ogawa K, Yanagihara K, Yamamoto Y, Miyamoto J, Tashiro T, Kohno S (1997) Rapid prediction of rifampin susceptibility of Mycobacterium tuberculosis. Am J Respir Crit Care Med 155:2057–2063PubMed
24.
Zurück zum Zitat Torres MJ, Criado A, Palomares JC, Aznar J (2000) Use of real-time PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in Mycobacterium tuberculosis. J Clin Microbiol 38:3194–3199PubMed Torres MJ, Criado A, Palomares JC, Aznar J (2000) Use of real-time PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in Mycobacterium tuberculosis. J Clin Microbiol 38:3194–3199PubMed
Metadaten
Titel
Risk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients
verfasst von
V. C. C. Cheng
W. C. Yam
P. C. Y. Woo
S. K. P. Lau
I. F. N. Hung
S. P. Y. Wong
W. C. Cheung
K. Y. Yuen
Publikationsdatum
01.10.2003
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 10/2003
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-0998-z

Weitere Artikel der Ausgabe 10/2003

European Journal of Clinical Microbiology & Infectious Diseases 10/2003 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.